Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 2 days agoScore90
Body · original
TALENT—neoadj TDXd (6-8 cycles) +/- AI in HER2 low HR+ early stage breast ca
ypCR // RCB
TDXd 7% // 16%
T-DXd/AI: 3% // 9%
T-DXd→ TC: 17% // 17%
Author concludes “modest” benefit; I would say “disappointing”. ypCR just isn’t the same endpoint w/ ER+ disease #ESMO26 @OncoAlert
564 views · 17 likes · 8 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com